Apogee Therapeutics (APGE) Enterprise Value (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Enterprise Value data on file, last reported at -$1.1 billion in Q1 2026.

• On a quarterly basis, Enterprise Value fell 106.48% year-over-year to -$1.1 billion in Q1 2026; TTM through Mar 2026 was -$1.1 billion, a 106.48% decrease from a year earlier, with the FY2025 full-year figure at -$730.2 million, down 40.25% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.1 billion, down from -$730.2 million in the prior quarter.
• Over the last five years, Enterprise Value for APGE reached as high as -$5.0 million in Q2 2022 and fell as low as -$1.1 billion in Q1 2026.
• Historically, Enterprise Value has averaged -$498.2 million across 5 years, with a median of -$517.0 million in 2024.
• Across the five-year window, Enterprise Value slumped 2414.46% in 2023 and soared 37.11% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$151.9 million in 2022, then sank by 160.36% to -$395.5 million in 2023, then sank by 31.66% to -$520.7 million in 2024, then slumped by 40.25% to -$730.2 million in 2025, then plunged by 45.15% to -$1.1 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$1.1 billion in Q1 2026, -$730.2 million in Q4 2025, and -$527.3 million in Q3 2025.